1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Commentary
Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466)
Article first published online: 11 FEB 2010
DOI: 10.1002/cncr.24950
Copyright © 2010 American Cancer Society
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Additional Information
How to Cite
Linz, U. (2010), Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). Cancer, 116: 1844–1846. doi: 10.1002/cncr.24950
Publication History
- Issue published online: 6 APR 2010
- Article first published online: 11 FEB 2010
- Manuscript Accepted: 5 AUG 2009
- Manuscript Revised: 28 JUL 2009
- Manuscript Received: 17 JUN 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- glioblastoma;
- chemotherapy;
- temozolomide;
- nimustine;
- Neuro-Oncology Working Group of the German Cancer Society;
- European Organization for Research and Treatment of Cancer
Abstract
Recently, un update of the important European Organization for Research and Treatment of Cancer study 26981 was published without correcting deficiencies that already were known and publicized in 2008. In the current commentary, the author specifies those issues to help prevent incorrect conclusions and discusses reasons why the journal that published the update dismissed a letter clarifying those shortcomings. Cancer 2010. © 2010 American Cancer Society.